March 13th 2023
Your daily dose of clinical news you may have missed.
Research on myocarditis has found the risk for the condition significantly higher from infection with SARS-CoV-2 vs from mRNA vaccination against it. True or False?
For vaccine-hesitant patients concerned about myocarditis, it may be helpful to provide real-world context. The quiz contains tips on how to do that.
March 9th 2023
ACC 2023. Electronic nudges highlighting the potential cardiovascular benefits of flu vaccination led to a modest uptake in vaccination rates among older adults in Denmark, according to results of the NUDGE-FLU trial.
March 3rd 2023
Data presented at CROI 2023 demonstrated that periods of reinfection with the virus correlated with ascent of new variants and with time since first infection.
FDA Advisory Committee Votes in Support of Safety, Efficacy of GSK Adult RSV Vaccine Candidate
The VRBPAC vote that the GSK data support the vaccine's efficacy was unanimous and on safety the vote was 10-2. PDUFA date set for May, 2023.
COVID-19 Vaccination May Reduce Post-infection Risk for Major Cardiovascular Events
The study of more than 1.9 million US residents is the first to investigate a link between both full and partial COVID-19 vaccination and future CV risk.
Daily Dose: Vaccine-preventable Viruses & Neurodegenerative Disease
Daily Dose: COVID-19 Infection Increases Risk of Type 2 Diabetes
Vaccine-preventable Viruses Associated with Increased Risk for Neurodegenerative Disease: NIH Findings
The large biobank-based study found 22 pairings of a neurodegenerative disorder and a previous viral infection. Vaccines exist against several of those viruses.
Cedars-Sinai Study Said to Confirm Increased Risk of New-onset T2D After COVID-19 Infection
The EHR analysis found greater risk of type 2 diabetes after COVID regardless of vaccination status although odds were greater for those unvaccinated before infection.
Changes to the ACIP 2023 Adult Immunization Schedule
Get a quick topline look at specific revisions and additions included in the ACIP's recommendations for routine immunization of those aged ≥19 years in the US.
One Office Visit, Multiple Vaccines: When is it OK?
Administering multiple vaccines at the same visit is shown to increase vaccination rates but is not always advisable. Try this quiz on 2 clinical scenarios.
Cash for Vaccination: Is it Effective? Is it Good Policy?
Lotteries with cash incentives and other giveaways are just one example of ways the COVID-19 pandemic changed the way US health care is handled.
How to Handle Medical Misinformation in the Clinic
These tips from a family physician on managing misinformation in the exam room can help reduce the spread of false and misleading narratives.
The COVID-19 Vaccine Halo Effect: Survey Highlights
The Kaiser Family Foundation survey found a 10% drop in the proportion of adults who say MMR vaccination should be required for school attendance, and other "halo" effects.
CDC Releases First Estimates of Bivalent mRNA COVID-19 Booster Effectiveness against XBB/XBB.1.5
Preliminary estimates showed relative bivalent booster dose vaccine effectiveness against XBB/XBB.1.5 for at least the first 3 months after vaccination.
Moderna Reports Adult RSV Vaccine Efficacy of 84% in Phase 3 ConquerRSV Trial
The mRNA vaccine returned efficacy of 83.7% against RSV-associated lower respiratory tract disease defined by ≥2 symptoms and of 82.4% against disease defined by ≥3 symptoms.
Long COVID After Mild Infection: Most Symptoms Resolve After 1 Year, Finds Large Israeli Study
Overall dyspnea was the most common symptom of long COVID in the first year after infection, according to the nationwide retrospective cohort study.
CDC Real-world Studies Show Bivalent Boosters Protect Against Severe COVID-19 Disease
One study showed the boosters provide significant protection against hospitalization and ED care and the other found vaccine effectiveness of 84% in older adults.
COVID-19 Vaccines Have Saved 3 Million Lives in the 2 Years Since the First EUA
The vaccination campaign in the US also has prevented more than 18 million hospitalizations and saved $1 trillion in medical costs, according to a modeling study.
FDA Grants Priority Review to Pfizer’s RSV Vaccine Candidate for Older Americans
The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for adults aged ≥60 years.
Vaccine Confidence Significantly Eroded During Pandemic, Across Demographics
Confidence in vaccines is lower post-pandemic across all demographic groups and is not limited to traditional "anti-vaxxers," say authors of a new study.
RSV Older Adult Vaccine Candidate from GSK Wins FDA Priority Review, PDUFA Date Set
The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.
Adult RSV Vaxx Gets EMA Nod: Can USA be Far Behind?
The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.
Recombinant Zoster Vaccine Protection Durable at 10 Years, New Study Finds
Efficacy of the RZV vaccine against herpes zoster infection remained >80% in a long-term follow-up study representing 10 years since initial immunization.
High-dose Influenza Vaccine Consistently More Effective vs Standard-dose in Older Adults: Meta-analysis
The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.
US FDA Grants EUA for Novavax COVID-19 Booster Shot
Another choice of booster may help increase follow-up vaccination among the 50% of US adults who have yet to get a first booster dose.
How to Talk to Patients about Coadministration of Influenza and COVID-19 Vaccines This Year
AAFP Board Chair Sterling Ransone, Jr, MD, encourages patients to get both shots at one visit; if they don't, he has strategies to bring them back for the one they didn't get.
AAFP Tips on Getting Shots into Arms this Flu Season with Sterling Ransone, Jr, MD
AAFP Board Chair Sterling Ransone, Jr, MD, offers an Academy refresher on the annual push-back from patients that is so familiar to family medicine clinicians.
GSK Announces Positive Pivotal Phase 3 Data for Adult RSV Vaccine Candidate
The investigational respiratory syncytial virus vaccine had an overall efficacy of 82.6% against RSV-LRTD, 94.6% against severe disease, and 94.1% in adults with comorbidities.
Americans Have not Been Truthful about Following COVID-19 Precautions
More than 4 in 10 US adults have either misrepresented their COVID-19 status or failed to adhere to public health measures. A new survey found out why.
Phase 3 Trial Now Underway of Investigational mRNA-based Influenza Vaccine
Pfizer announced that the first participants have been dosed in a novel phase 3 efficacy clinical trial of its quadrivalent modified RNA influenza vaccine candidate.
COVID-19 mRNA Vaccines Found Safe in Patients with Heart Failure in Real-world Study
ESC 2022: SARS-CoV-2 mRNA vaccines were not associated with an increased risk of worsening heart failure, venous thromboembolism, or myocarditis in a large Danish real-world study.
Pfizer Reports Positive Topline Phase 3 Data for Bivalent RSV Vaccine in Older Adults
Pfizer announced that a single dose of the vaccine, RSVpreF, demonstrated 85.7% efficacy against severe disease, defined by ≥3 symptoms.
2 Clarke Drive Cranbury, NJ 08512